Clinical Trials Browser

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2 Recruiting

153 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06124157 2026-03-13

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 3 Recruiting

222 enrolled

Lymphoid

Burkitt Lymphoma

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

Phase 1 Recruiting

24 enrolled

Lymphoid

Burkitt Lymphoma

NCT06533748 2026-02-12

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Phase 2 Recruiting

128 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05848687 2026-01-13

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Phase 1/2 Recruiting

90 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03571321 2026-01-09

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Phase 1 Recruiting

15 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Recruiting

160 enrolled

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06387121 2025-12-17

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Phase 2 Recruiting

53 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT05645718 2025-10-07

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Phase 2 Recruiting

27 enrolled

Other hematologic neoplasm

Leukemia

NCT04440267 2025-08-06

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Phase 2 Recruiting

50 enrolled

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute

NCT05660473 2025-08-01

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Phase 2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06199557 2025-06-29

HUVAMER

Phase 1/2 Recruiting

48 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05959720 2025-05-07

BRALLA

Recruiting

180 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03643276 2025-04-06

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Phase 3 Recruiting

5,000 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04043494 2025-03-21

LBL 2018

Phase 3 Recruiting

683 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05506332 2022-08-18

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute